Cambridge, UK, 20th September 2018 / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly during his tenure, delivering numerous development candidates across several therapeutic areas.
Following his education at the University of Cambridge, Dr Perrior undertook academic research at Cambridge, Oxford and in the USA. He then held senior R&D roles in pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, USA and Switzerland. Dr Perrior is also a scientific consultant to a number of venture capital and charitable organisations and is the Visiting Professor of Medicinal Chemistry at The University of Sussex.
“I am delighted to formalise Trevor’s leadership position in the company," said Dr Timo Veromaa, Executive Chairman. “The Executive Team was recently strengthened by Chris Brown joining as CFO and with Tom Mander as COO continuing to lead business development, I am confident the company is well positioned as a high quality service provider. With Trevor now taking the helm I will step down and Tony Brampton will resume duties as non-executive chairman.”
“I am honoured to be offered this exciting opportunity to lead Domainex into a new growth period,” commented Dr Perrior. “I believe we are in a strong position to build on our expanding scientific capabilities to serve our global client base. I look forward to working with the whole Domainex team to devise and implement our future growth strategies in drug research services. We aim to further increase our business in mainland Europe and in the USA where we have just opened two sales offices. Finally, I would like to thank Timo for his insightful contributions and leadership over the past 2 years, which have been very valuable to us during this transition period, and wish him well in his future endeavours.”
For more information contact:
Media Relations – Sciad Communications
Deborah Cockerill / Juliette Craggs / Emma Pickup
T: +44(0)20 7470 8801
E: domainex@sciad.com
Notes to Editors
About Domainex
Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned company that provides integrated medicines research services to global pharmaceutical, biotechnology and academic partners. Its services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads with its ‘every compound counts’ approach, which can save up to 30% on the average industry time from target to candidate.